

Veronique Rogemond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8185855/publications.pdf>

Version: 2024-02-01

81
papers

5,345
citations

53794

45
h-index

85541

71
g-index

82
all docs

82
docs citations

82
times ranked

4773
citing authors

#	ARTICLE	IF	CITATIONS
1	Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis. Journal of Neurology, 2022, 269, 377-388.	3.6	10
2	Glial Fibrillary Acidic Protein Autoimmunity. Neurology, 2022, 98, .	1.1	61
3	Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
4	Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology, 2021, 96, e866-e875.	1.1	44
5	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	1.3	14
6	Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications, 2021, 3, fcab185.	3.3	28
7	Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	43
8	Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
9	Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1076-1084.	1.9	53
10	Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	74
11	Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. Journal of Neurology, 2020, 267, 1906-1911.	3.6	18
12	Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum, 2020, 19, 715-721.	2.5	9
13	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	58
14	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. Journal of Neurology, 2020, 267, 2083-2089.	3.6	28
15	Central nervous system complications associated with immune checkpoint inhibitors. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 772-778.	1.9	92
16	Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	74
17	Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	129
18	Human Autoantibodies Against N-Methyl-D-Aspartate Receptor Modestly Alter Dopamine D1 Receptor Surface Dynamics. Frontiers in Psychiatry, 2019, 10, 670.	2.6	18

#	ARTICLE	IF	CITATIONS
19	Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 38.	5.2	62
20	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. <i>Journal of Neurology</i> , 2019, 266, 195-206.	3.6	58
21	TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. <i>Cerebellum</i> , 2019, 18, 245-254.	2.5	44
22	Multiplex family with GAD65-Abs neurologic syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e416.	6.0	16
23	Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. <i>Journal of Neuroimmunology</i> , 2018, 315, 28-32.	2.3	17
24	Effect of thymectomy on refractory autoimmune status epilepticus. <i>Journal of Neuroimmunology</i> , 2018, 317, 90-94.	2.3	13
25	Initial clinical presentation of young children with N-methyl- d -aspartate receptor encephalitis. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 404-411.	1.6	26
26	Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. <i>Journal of Neurology</i> , 2018, 265, 2190-2200.	3.6	64
27	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017, 88, 514-524.	1.1	49
28	Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. <i>Nature Communications</i> , 2017, 8, 1791.	12.8	103
29	Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e371.	6.0	64
30	Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. <i>Biological Psychiatry</i> , 2017, 82, 766-772.	1.3	67
31	Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 491-499.	5.6	103
32	Clinical and autoimmune features of a patient with autism spectrum disorder seropositive for anti-NMDA-receptor autoantibody. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 65-70.	3.7	16
33	Neuroleptic intolerance in patients with anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e280.	6.0	139
34	Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. <i>JAMA Neurology</i> , 2016, 73, 1115.	9.0	155
35	Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. <i>Brain</i> , 2016, 139, 1079-1093.	7.6	157
36	Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 265.	3.7	54

#	ARTICLE	IF	CITATIONS
37	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. <i>Journal of Neurology</i> , 2015, 262, 1859-1866.	3.6	105
38	CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e166.	6.0	18
39	Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1347-1355.	1.9	48
40	Clinical Spectrum of Encephalitis Associated With Antibodies Against the \pm -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. <i>JAMA Neurology</i> , 2015, 72, 1163.	9.0	123
41	Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e68.	6.0	25
42	Intrathecal treatment of anti-N-methyl-D-aspartate receptor encephalitis in children. <i>Developmental Medicine and Child Neurology</i> , 2015, 57, 95-99.	2.1	48
43	Collapsin Response Mediator Protein 5 (CRMP5) Induces Mitophagy, Thereby Regulating Mitochondrion Numbers in Dendrites. <i>Journal of Biological Chemistry</i> , 2014, 289, 2261-2276.	3.4	17
44	Surface dynamics of GluN2B-NMDA receptors controls plasticity of maturing glutamate synapses. <i>EMBO Journal</i> , 2014, 33, 842-861.	7.8	101
45	Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. <i>Neurology</i> , 2014, 82, 556-563.	1.1	202
46	Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis. <i>Journal of Infection</i> , 2014, 68, 419-425.	3.3	19
47	An Ion Channel Chip for Diagnosis and Prognosis of Autoimmune Neurological Disorders. <i>Recent Patents on CNS Drug Discovery</i> , 2014, 8, 171-179.	0.9	0
48	Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. <i>Journal of Cell Science</i> , 2013, 126, 4262-73.	2.0	21
49	Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. <i>Experimental Cell Research</i> , 2013, 319, 588-599.	2.6	11
50	Aquaporin-4 antibody-negative neuromyelitis optica. <i>Neurology</i> , 2013, 80, 2194-2200.	1.1	157
51	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. <i>Neurology</i> , 2013, 80, 2226-2232.	1.1	68
52	Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. <i>Brain</i> , 2012, 135, 1606-1621.	7.6	272
53	Full recovery of agrypnia associated with anti-Lgi1 antibodies encephalitis under immunomodulatory treatment: A case report with sequential polysomnographic assessment. <i>Sleep Medicine</i> , 2012, 13, 554-556.	1.6	19
54	Drug Binding Assays do not Reveal Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP2). <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 493-500.	3.9	33

#	ARTICLE	IF	CITATIONS
55	Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. <i>Journal of Neurology</i> , 2011, 258, 27-33.	3.6	36
56	Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 3.	2.7	75
57	VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13782-13787.	7.1	41
58	Facial pain as first manifestation of anti-Hu paraneoplastic syndrome. <i>Journal of Headache and Pain</i> , 2010, 11, 355-357.	6.0	13
59	HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. <i>Journal of Neuroimmunology</i> , 2010, 226, 147-149.	2.3	23
60	Delayed onset of a second paraneoplastic neurological syndrome in eight patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 937-939.	1.9	31
61	Metabotropic Glutamate Receptor Type 1 Autoantibody-Associated Cerebellitis. <i>Archives of Neurology</i> , 2010, 67, 627-30.	4.5	99
62	Collapsin Response Mediator Protein 4a (CRMP4a) Is Upregulated in Motoneurons of Mutant SOD1 Mice and Can Trigger Motoneuron Axonal Degeneration and Cell Death. <i>Journal of Neuroscience</i> , 2010, 30, 785-796.	3.6	53
63	CRMP5 Interacts with Tubulin to Inhibit Neurite Outgrowth, Thereby Modulating the Function of CRMP2. <i>Journal of Neuroscience</i> , 2010, 30, 10639-10654.	3.6	62
64	Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. <i>Brain</i> , 2010, 133, 2578-2591.	7.6	180
65	In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. <i>Orphanet Journal of Rare Diseases</i> , 2010, 5, 31.	2.7	102
66	Phosphorylation of Collapsin Response Mediator Protein 2 on Tyr-479 Regulates CXCL12-induced T Lymphocyte Migration. <i>Journal of Biological Chemistry</i> , 2009, 284, 13265-13276.	3.4	47
67	Processing and Nuclear Localization of CRMP2 during Brain Development Induce Neurite Outgrowth Inhibition. <i>Journal of Biological Chemistry</i> , 2008, 283, 14751-14761.	3.4	46
68	Extensive Expression of Collapsin Response Mediator Protein 5 (CRMP5) is a Specific Marker of High-grade Lung Neuroendocrine Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1699-1708.	3.7	31
69	Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. <i>Annals of Neurology</i> , 2007, 61, 544-551.	5.3	218
70	Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. <i>Journal of Neurochemistry</i> , 2006, 98, 1252-1265.	3.9	73
71	Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1 ^{-/-} mice. <i>Genes To Cells</i> , 2006, 11, 1337-1352.	1.2	43
72	Expression of collapsin response mediator proteins 1, 2 and 5 is differentially regulated in newly generated and mature neurons of the adult olfactory system. <i>European Journal of Neuroscience</i> , 2005, 21, 2635-2648.	2.6	38

#	ARTICLE	IF	CITATIONS
73	Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. <i>Journal of Comparative Neurology</i> , 2005, 486, 1-17.	1.6	105
74	A Role for the Neuronal Protein Collapsin Response Mediator Protein 2 in T Lymphocyte Polarization and Migration. <i>Journal of Immunology</i> , 2005, 175, 7650-7660.	0.8	64
75	Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 433-443.	2.2	69
76	Collapsin Response Mediator Proteins (CRMPs): Involvement in Nervous System Development and Adult Neurodegenerative Disorders. <i>Molecular Neurobiology</i> , 2003, 28, 51-64.	4.0	244
77	Isolation and Expression Pattern of Human Unc-33-Like Phosphoprotein 6/Collapsin Response Mediator Protein 5 (Ulip6/CRMP5): Coexistence with Ulip2/CRMP2 in Sema3A- Sensitive Oligodendrocytes. <i>Journal of Neuroscience</i> , 2001, 21, 7203-7214.	3.6	126
78	Anti-CV2 Autoantibodies and Paraneoplastic Neurological Syndromes. <i>Clinical Reviews in Allergy and Immunology</i> , 2000, 19, 51-60.	6.5	40
79	Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. <i>European Journal of Neuroscience</i> , 1999, 11, 4226-4232.	2.6	65
80	Formation of Stable and Functional HIV-1 Nucleoprotein Complexes in Vitro. <i>Journal of Molecular Biology</i> , 1995, 252, 563-571.	4.2	127
81	Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies. <i>Journal of Neurology</i> , 0, , .	3.6	8